Revolutionizing the treatment for hypothyroidism

Purpose and goal:

During the project period, we have initiated negotiations with a pharma partner regarding a license agreement. We have also validated the market need and size as well as the business model together with a third party contractor. Among other things, this has enabled a capitalization of the company. Finally, we have produced proof-of-concept data that has led to an additional patent application.

Expected results and effects:

Current hypothyroidism treatment does not lead to clinical benefit, ie symptomatic patient relief in the majority of patients. This remains one of the biggest societal challenges in global medical healthcare. Prolevi´s technology will lead to both general and specific symptomatic relief, better than existing alternatives. Through the project, we have built a foundation for continued development by validating the market and technology.

Approach and implementation:

We focused on getting quotes from different vendors for market analysis and networked with key equity and pharma partners. For market analysis a pricing estimation, valuation services, competition analysis and comparable deal structure were performed. For equity and pharma partnerships, we focused on local and international conferences such as NLSD, LSX and Bio-Europe. We are in leading term sheet discussions with pharma partner and multiple leads for equity partners.